Histoblood Group Antigens as a Risk Factor of Asthma
NCT00201266
Asthma, Bronchial Diseases
San Francisco, California, United States
View Trial DetailsNCT Number: NCT00006511
To identify gene variants in human chromosome 5Q31-33 that may be involved in the pathogenesis of asthma.
Looking for future studies?
Notify MeUp to 100 year
Male
Observational
BACKGROUND:
Markers and genes in chromosomal region 5q31-33 have been shown to be linked or associated to asthma or components of the asthma phenotype, suggesting that this chromosomal region is important in the genetic susceptibility to asthma, yet it has been difficult to show that a specific gene in this region plays a major role in asthma development or progression. Some of this difficulty arises from the fact that many genes are likely to be involved in the pathogenesis of asthma, with no single gene having an effect that will emerge as a major contributor, as well as the fact that the strong influence of environmental factors will complicate the analyses. Having recognized these issues, the investigators will use components of the asthma-associated phenotype, including eosinophilia and a compound "atopy" phenotype, to identify relevant asthma-related genes in this region. The identification of the genes and their genetic variants that may be associated with asthma and its related phenotypes may provide important new information on the pathogenesis of asthma.
The study is in response to a Request for Applications on "Positional Candidate Approaches in Asthma Gene Discovery" released in October 1999.
DESIGN NARRATIVE:
Dr. Martinez and his group have found linkage between markers in chromosome 5q31 and both eosinophilia and a composite 'atopy' phenotype. The goal of the study is to identify the gene variants in 5q31-33 that are responsible for these two linkage signals. This will be done using the same population of families enrolled in the Tucson Children's Respiratory Study that have now been followed since the time of birth of the index child approximately 18 years ago. In the first specific aim, gene variants having a frequency of 2% or more in a group of 25 known genes in chromosome 5q will be identified. The 25 genes have been selected among those that have been mapped to the 28 cM interval that was tested for linkage in previous studies. The second specific aim is to perform linkage disequilibrium mapping using 100 known polymorphisms in the region of approximately 6.4 cM that shows the highest likelihood of containing the gene variants responsible for either or both of the eosinophilia and atopy linkage signals. Detailed local mapping using both published and newly discovered polymorphisms in and around the areas of positive signals will also be performed. Based on the previous experience of these investigators for the same chromosomal region, several association/linkage signals in chromosome 5q are expected to be found.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
No eligibility criteria
National Heart, Lung, and Blood Institute (NHLBI)
Nih
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00201266
Asthma, Bronchial Diseases
San Francisco, California, United States
View Trial DetailsNCT04170348
Acute Chest Syndrome, Anemia
New York, United States
View Trial DetailsNCT06272370
Asthma, Bronchial Diseases
Aurora, Colorado, United States
View Trial DetailsNCT00005736
Asthma, Bronchial Diseases
View Trial Details